ArticleOncology and therapy2025
Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study.
Article in Oncology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe OVOC study was carried out to evaluate the management and clinical evolution of patients with advanced ovarian cancer (AOC) in routine clinical practice in Spain.
methodsA retrospective study was made in women diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO IIIB-IV) who had received at least one line of treatment between 2013 and 2016, before the establishment of poly ADP ribose polymerase (PARP) inhibitors as first-line treatment.
resultsA total of 400 patients (median age: 61.7 years; FIGO IIIC: 60.0%; high-grade serous carcinoma: 75.0%) received a median of two therapy lines. Primary and interval debulking surgery was performed in 37.0% and 54.3% of the patients. Germline BRCA1 and BRCA2 mutations were found in 16.2% and 12.0% of the patients. The median progression-free survival (PFS) from the start of the first-/second-/third-line of treatment was 14.2/8.7/4.5 months. The median treatment-free interval (TFI) to the start of the second line was 9.9 months. The median overall survival (OS) was 42.6 months. At first relapse, 65.9% of the patients were platinum-sensitive and 34.1% platinum-resistant. Biologic therapies were administered in 25.2% of the platinum-sensitive and 16.2% of the platinum-resistant patients. Patients harboring BRCA mutations had a lower risk of progression/relapse after the first (BRCA1 and BRCA2 mutation versus native: p < 0.0001) and second line (BRCA1 and BRCA2 mutation versus native: p = 0.021 and p = 0.037, respectively). Patients with BRCA2 mutations had a lower mortality risk than those without (p = 0.015). The median PFS was significantly higher in patients receiving targeted therapy in the first (17.4 versus 11.6 months; p = 0.039) and second line (11.1 versus 7.8 months; p < 0.001).
conclusionThis study provides real-world data on therapeutic management and outcomes in AOC patients in Spain. A longer PFS was achieved in patients receiving targeted therapies. BRCA1/2 mutations were a favorable prognostic factor for PFS and BRCA2 mutation for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.